Human carcinoma-associated antigen (HCA), isolated from the endometrial carcinoma cell line KLE-1 and ascitic fluid of a patient with ovarian carcinoma; comparison with epiglycanin

European Journal of Pharmaceutical Sciences

Volumn 6, Issue 2, 1998, Pages 121-129

  Thingstad, Torunn ^a   Haavik, Svein ^a   Hansen, Katrine ^a   Sletten, Knut ^c   Codington, John F ^b   Barsett, Hilde ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Epiglycanin; Human carcinoma antigen; KLE 1; Mucin type glycoprotein; Ovarian carcinoma

Indexed keywords

TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; ASCITES FLUID; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ISOLATION;

AGED; ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; ASCITIC FLUID; CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INTEGRIN ALPHA6BETA4; INTEGRINS; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0032055554     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(97)00076-6     Document Type: Article

References (34)

1. Bhavanandan V.P. Malignancy-related cell surface mucin-type glycoproteins. Ind. J. Biochem. Biophys. 25:1988;36-42.
2. Carraway K.L., Spielman J. Structural and functional aspects of tumor cell sialomucins. Mol. Cell. Biochem. 72:1986;109-120.
3. Codington J.F., Haavik S. Epiglycanin - a carcinoma-specific mucin-type glycoprotein of the mouse TA3 tumour. Glycobiology. 2:1992;173-180.
4. Codington J.F., Sanford B.H., Jeanloz R.W. Glycoprotein coat of the TA3 cell. Isolation and partial characterization of a sialic acid containing glycoprotein fraction. Biochemistry. 11:1972;2559-2564.
5. Codington J.F., Cooper A.G., Miller D.K., Slayter H.S., Brown M.C., Silber C., Jeanloz R.W. Isolation and partial characterization of an epiglycanin-like glycoprotein from a new non-strain-specific subline of TA3 murine mammary adenocarcinoma. J. Natl. Cancer Inst. 63:1979;153-161.
6. Codington J.F., Das H.R., Dalianis T., Klein G., Miller S.C., Silber C., Lampert L.A., Darby D.M., Jeanloz R.W. Cell surface characteristics of an allotransplantable TA3 ascites subline resulting from a process of immunoselection. Cancer Res. 43:1983;4373-4381.
7. Codington J.F., Bhavanandan V.P., Block K., Nikrui N., Ellard J.V., Wang P.S., Jeanloz R.W. Antibody to epiglycanin and radioimmunoassay to detect epiglycanin-related glycoproteins in body fluids of cancer patients. J. Natl. Cancer Inst. 73:1984;1029-1038.
8. Codington J.F., Haavik S., Hui Z., Matson S., Wu Z., Chen X. Immunoassays for determining the concentration of a carcinoma-specific antigen in the blood of cancer. Glycoconjugate J. 10:1993;319.
9. Cooper A.G., Codington J.F., Brown M.C. In vivo release of glycoprotein I from the Ha subline of TA3 murine tumor into ascites fluid and serum. Proc. Natl. Acad. Sci. USA. 71:1974;1224-1228.
10. Cooper A.G., Codington J.F., Miller D.K., Brown M.C. Loss of strain specificity of the TA3-St subline: evidence for the role of epiglycanin in mouse allogeneic tumor growth. J. Natl. Cancer Inst. 63:1979;163-169.
11. Dahiya R., Kwak K.S., Byrd J.C., Ho S., Yoon W.H., Kim Y.S. Mucin synthesis and secretion in various human epithelial cancer cell lines that express the MUC-1 mucin gene. Cancer Res. 53:1993;1437-1443.
12. Decaens C., Nardelli J., Bara J., Burtin P. Biochemical characterization of a rat oncofetal colonic antigen defined by a monoclonal antibody raised against gastric surface epithelium. Biochem. J. 293:1993;531-536.
13. Devaraj N., Devaraj H., Bhavanandan V.P. Purification of mucin glycoproteins by density gradient centrifugation in cesium trifluoroacetate. Anal. Biochem. 206:1992;142-146.
14. Dubois M., Gilles K.A., Hamilton J.K., Rebers P.A., Smith F. Colorimetric method for determination of sugars and related substances. Anal. Chem. 28:1956;350-356.
15. Fung P.Y.S., Longenencker M.L. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res. 51:1991;1170-1176.
16. Galfre G., Milstein C. Preparation of monoclonal antibodies: Strategies and procedures. Methods Enzymol. 73(Part B):1981;3-46.
17. Haavik S., Codington J.F., Davison P.F. Development and characterization of monoclonal antibodies against a mucin type glycoprotein. Glycobiology. 2:1992;217-224.
18. Hilkens J., Buijs F. Biosynthesis of MAM-6, an epithelial sialomucin. J. Biol. Chem. 263:1988;4215-4222.
19. Hilkens J. Biochemistry and function of mucins in malignant disease. Cancer Rev. 11/12:1988;25-54.
20. Ho J.J.L., Bi N., Siddiki B., Chung Y.S., Yuan M., Kim Y.S. Multiple forms of intracellular and secreted mucins in a pancreatic cancer cell line. Cancer Res. 53:1993;884-890.
21. Horan Hand P., Calvo B., Milenic D., Yokota T., Finch M., Snoy P., Garmestani K., Gansow O., Schlom J., Kashmiri S.V.S. Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant. Cancer Immunol. Immunother. 35:1992;165-174.
22. Kemperman H., Wijnands Y., Wesseling J., Niessen C.M., Sonnenberg A., Roos E. The mucin epiglycanin on TA3/Ha carcinoma cells prevents α(6)ß(4)-mediated adhesion to laminin and kalinin and E-cadherin-mediated cell-cell interaction. J. Cell Biol. 127:1994;2071-2080.
23. Laemmli U.K. Clevage of structural proteins during the assembly of the head of bacteriophage T 4. Nature. 227:1970;680-685.
24. Lan M.S., Finn O.J., Fernsten P.D., Metzgar R.S. Isolation and properties of a human pancreatic adenocarcinoma-associated antigen, DU-PAN-2. Cancer Res. 45:1985;305-310.
25. Lan M.S., Batra S.K., Qi W.-N., Metzgar R.S., Hollingsworth M.A. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J. Biol. Chem. 265:1990;15294-15299.
26. Nishida K., Ueda R., Sakakibara K., Minoura Y., Ohta M., Ariyoshi Y., Takahashi T. Characterization of OM-B Monoclonal antibody-defined antigen associated with mucinous type human ovarian tumor. Jpn. J. Cancer Res. 84:1993;65-74.
27. Pancino G., Osinaga E., Charpin C., Mistro D., Barque J.Ph., Roseto A. Purification and characterization of a breast-cancer-assosiated glycoprotein not expressed in normal breast and identified by monoclonal antibody 83D4. Br. J. Cancer. 63:1991;390-398.
28. Richardson G.S., Dickersin R., Atkins L., MacLaughlin D.T., Raam S., Merk L.P., Bradley F.M. KLE: A cell line with defective estrogen receptor derived from undifferentiated endometrial cancer. Gynecol. Oncol. 17:1984;213-230.
29. Sheer D.G., Schlom J., Cooper H.L. Purification of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res. 48:1988;6811-6818.
30. Spicer A.P., Parry G., Patton S., Gendler S.J. Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential o-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. J. Biol. Chem. 266:1991;15099-15109.
31. Springer G.F. T and Tn, general carcinoma autoantigens. Science. 224:1984;1198-1206.
32. Van den Eijnden D.H., Evans N.A., Codington J.F., Reinhold V., Silber C., Jeanloz R.W. Chemical structure of epiglycanin, the major glycoprotein of the TA3-Ha ascites cell. J. Biol. Chem. 254:1979;12153-12159.
33. Warren L., Buck C.A., Tuszynski G.P. Glycopeptide changes and malignant transformation a possible role for carbohydrate in malignant behavior. Biochim. Biophys. Acta. 516:1978;97-127.
34. Wu K., Fregien N., Carraway K.L. Molecular cloning and sequencing of the mucin subunit of a heterodimeric, bifunctional cell surface glycoprotein complex of ascites rat mammary adenocarcinoma cells. J. Biol. Chem. 269:1994;11950-11955.